感官在2024年9月20日举行的世界听力学大会上宣布了SENS-501和SENS-401听力损失疗法的临床积极结果。 Sensorion announces positive clinical results for hearing loss therapies SENS-501 and SENS-401 at the World Congress of Audiology on September 20, 2024.

一家侧重于听力损失治疗的临床阶段生物技术公司Sensorion在2024年9月20日世界听力学大会上宣布其SENS-501和SENS-401方案取得积极的临床结果。 Sensorion, a clinical-stage biotech firm focused on hearing loss therapies, announced positive clinical results for its SENS-501 and SENS-401 programs at the World Congress of Audiology on September 20, 2024. 首席执行官Nawal Ouzren强调,该公司在旨在恢复和预防听力损失的创新处理办法方面取得了进展。 CEO Nawal Ouzren emphasized the company's advancements in innovative treatments aimed at restoring and preventing hearing loss. 此外,Sensorion还发表了《2024年年中报告》,详细介绍了其财务业绩,可在其网站上查阅。 Additionally, Sensorion has released its Half Year 2024 Report, detailing its financial performance, accessible on their website.